BioNTech SE (NASDAQ:BNTX) Shares Sold by Voloridge Investment Management LLC

Voloridge Investment Management LLC decreased its position in shares of BioNTech SE (NASDAQ:BNTX) by 12.3% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 351,095 shares of the company’s stock after selling 49,211 shares during the period. Voloridge Investment Management LLC’s holdings in BioNTech were worth $40,007,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tema Etfs LLC purchased a new position in shares of BioNTech during the 4th quarter worth $513,000. Stempoint Capital LP purchased a new stake in BioNTech in the 4th quarter valued at about $6,997,000. Shell Asset Management Co. acquired a new position in shares of BioNTech during the 4th quarter valued at about $2,215,000. Raiffeisen Bank International AG purchased a new position in shares of BioNTech during the 4th quarter worth about $1,126,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of BioNTech in the fourth quarter worth approximately $1,014,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on BNTX shares. Citigroup reaffirmed a “buy” rating and set a $140.00 price target (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Morgan Stanley cut their target price on BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 6th. BMO Capital Markets lifted their target price on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and set a $134.00 price target (down from $145.00) on shares of BioNTech in a research note on Wednesday, May 14th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $142.08.

BioNTech Trading Up 4.0%

BNTX opened at $101.72 on Wednesday. The firm’s 50 day moving average is $97.45 and its 200-day moving average is $108.67. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $24.45 billion, a P/E ratio of -48.44 and a beta of 1.35.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the previous year, the firm posted $1.90 EPS. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. Analysts expect that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.